David Grainger
British life-sciences investor and drug developer, venture partner at Medicxi and chief executive of Methuselah Health.
Factos biográficos
Sem retrato sob licença livre disponível
- Cargo atual
- Venture Partner, Medicxi; Chief Executive, Methuselah Health
- Organização
- Medicxi
- País
- United Kingdom
Este artigo ainda não está disponível neste idioma. A versão em inglês é apresentada abaixo.
David Grainger (born 12 October 1966) is a British life-sciences investor and drug developer. He is a co-founder and venture partner of Medicxi, a European venture capital firm focused on life sciences, having previously worked in the life-sciences practice of Index Ventures.
He is chief executive of Methuselah Health, a United Kingdom company applying proteomics to the development of treatments for age-related disease, and was formerly Chief Innovation Officer of Centessa Pharmaceuticals.
Grainger has co-founded and chaired several biotechnology companies, among them XO1, later acquired by Janssen Pharmaceuticals, and Morphogen-IX, and led investments including Padlock Therapeutics, acquired by Bristol-Myers Squibb. He has also written on the pharmaceutical industry for Forbes.
Formação académica
- University of Cambridge